The Cancer Problem offers the first medical, cultural, and social history of cancer in nineteenth-century Britain. It begins by looking at a community of doctors and patients who lived and worked in the streets surrounding the Middlesex Hospital in London. It follows in their footsteps as they walked the labyrinthine lanes and passages that branched off Tottenham Court Road; then, through seven chapters, its focus expands to successively include the rivers, lakes, and forests of England, the mountains, poverty, and hunger of the four nations of the British Isles, the reluctant and resistant inhabitants of the British Empire, and the networks of scientists and doctors spread across Europe and North America. The Cancer Problem: Malignancy in Nineteenth-Century Britain argues that it was in the nineteenth century that cancer acquired the unique emotional, symbolic, and politicized status it maintains today. Through an interrogation of the construction, deployment, and emotional consequences of the disease's incurability, this book reframes our conceptualization of the relationship between medicine and modern life and reshapes our understanding of chronic and incurable maladies, both past and present.

Cancer is low or absent on the health agendas of low- and middle-income countries (LMCs) despite the fact that more people die from cancer in these countries than from AIDS and malaria combined. International health organizations, bilateral aid agencies, and major foundations—which are instrumental in setting health priorities—also have largely ignored cancer in these countries. This book identifies feasible, affordable steps for LMCs and their international partners to begin to reduce the cancer burden for current and future generations. Stemming the growth of cigarette smoking tops the list to prevent cancer and all the other major chronic diseases. Other priorities include infant vaccination against the hepatitis B virus to prevent liver cancers and vaccination to prevent cervical cancer. Developing and increasing capacity for cancer screening and treatment of highly curable cancers (including most childhood malignancies) can be accomplished using "resource-level appropriateness" as a guide. And there are ways to make inexpensive oral morphine available to ease the pain of the many who will still die from cancer.

In 1950, a diagnosis of cancer was all but a death sentence. Mortality rates only got worse, and as late as 1986, an article in the New England Journal of Medicine lamented: “We are losing the war against cancer.” Cancer is one of humankind's oldest and most persistent enemies; it has been called the existential disease. But we are now entering a new, and more positive, phase in this long campaign. While cancer has not been cured—and a cure may elude us for a long time yet—there has been a revolution in our understanding of its nature. Years of brilliant science have revealed how this individualistic disease seizes control of the foundations of life—our genes—and produces guerrilla cells that can attack and elude treatments. Armed with those insights, scientists have been developing more effective weapons and producing better outcomes for patients. Paul A. Marks, MD, has been a leader in these efforts to finally control this devastating disease. Marks helped establish the strategy for the “war on cancer” in 1971 as a researcher and member of President Nixon's cancer panel. As the president and chief executive officer for nineteen years at the world's pre-eminent cancer hospital, the Memorial Sloan-Kettering Cancer Center, he was instrumental in ending the years of futility. He also developed better therapies that promise a new era of cancer containment. Some cancers, like childhood leukemia and non-Hodgkin's lymphoma, that were once deadly conditions, are now survivable—even curable. New steps in prevention and early diagnosis are giving patients even more hope. On the Cancer Frontier is Marks' account of the transformation in our understanding of cancer and why there is growing optimism in our ability to stop it.

The statements about essential fats or the life threatening effects of certain fats and their significance for the cancer problem lead to a collision with prevailing opinion. Convinced of her scientific findings on the natural science level, Dr. Johanna Budwig devoted her life to the realization of the validity of her research results for sustaining human life in medicine, and in the process bring about a change in the direction of cancer research and therapy.

In 2005, 7.6 million people died of cancer. More than 70% of those deaths occured in low and middle income countries. WHO has developed a series of six modules that provides practical advice for programme managers and policy-makers on how to advocate, plan and implement effective cancer control programmes, particularly in low and middle income countries.The WHO guide is a response to the World Health Assembly resolution on cancer prevention and control (WHA58.22), adopted in May 2005, which calls on Member States to intensify action against cancer by developing and reinforcing cancer control programmes.

The book addresses controversies related to the origins of cancer and provides solutions to cancer management and prevention. It expands upon Otto Warburg's well-known theory that all cancer is a disease of energy metabolism. However, Warburg did not link his theory to the "hallmarks of cancer" and thus his theory was discredited. This book aims to provide evidence, through case studies, that cancer is primarily a metabolic disease requring metabolic solutions for its management and prevention. Support for this position is derived from critical assessment of current cancer theories. Brain cancer case studies are presented as a proof of principle for metabolic solutions to disease management, but similarities are drawn to other types of cancer, including breast and colon, due to the same cellular mutations that they demonstrate.

This atlas illustrates the latest available data on the cancer epidemic, showing causes, stages of development, and prevalence rates of different types of cancers by gender, income group, and region. It also examines the cost of the disease, both in terms of health care and commercial interests, and the steps being taken to curb the epidemic, from research and screening to cancer management programs and health education.